GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 139   

Articles published

GSK 39.47 -1.29 (-3.16%)
price chart
Will GlaxoSmithKline plc (ADR) Provide A Cure For Synovial Sarcoma?
Adaptimmune Therapeutics plc - ADR (NASDAQ:ADAP) and GlaxoSmithKline plc (ADR) (NYSE:GSK) have announced their enhanced collaborative efforts toward the former's lead clinical cancer program.
Revenue Update on GlaxoSmithKline plc (ADR)(NYSE:GSK)
GlaxoSmithKline plc (ADR)(NYSE:GSK) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during Pre-market on Feb 3, 2016.
Does GlaxoSmithKline plc (ADR) Have Any Gas After Today's Gap Down?  Sonoran Weekly Review
GlaxoSmithKline plc Can Pull Through Without a Split; Merrill Lynch Hikes ...
This Wednesday, GlaxoSmithKline plc (ADR) (NYSE:GSK) managed to deliver a slight fourth-quarter earnings beat, aided by increasing demand for its recently launched respiratory and HIV medicines.
GlaxoSmithKline plc (ADR) Tops Revenue, Misses Core Earnings
GlaxoSmithKline plc (NYSE:GSK) stock gained approximately 4% during pre-market hours today, after the company disclosed financial results for fourth quarter of fiscal year 2015 (4QFY15) and fiscal year 2015 (FY15).
Is The Proposed GlaxoSmithKline plc (ADR) Split Wise?
GlaxoSmithKline plc (ADR) (NYSE:GSK) may be in for some major restructuring. Neil Woodford, a veteran UK fund manager who holds the company in his equity income fund, is calling for a four-way split of GSK's operations, as per a latest report.
GlaxoSmithKline plc (ADR) (GSK): Stock Surges Post-Earnings  Business Finance News
GlaxoSmithKline plc (ADR) (GSK) Gets the Much Needed Boost to Deliver Better ...  InvestCorrectly
GlaxoSmithKline plc (ADR) Stock Update: Drug-Maker In Hot Water Again
British pharmaceutical giant GlaxoSmithKline Plc (ADR) (NYSE:GSK) has seen a gloomy stock performance so far this year, with only a few steep increases barely able to offset the many declines.
GlaxoSmithKline plc (ADR) (GSK) Stock Update: Mixed Signals For Investors
GlaxoSmithKline Plc (ADR) (NYSE:GSK) stock has performed moderately well so far this year, marked with some steep increases and declines as well.
GlaxoSmithKline plc (ADR): Why Nucala's FDA Approval Is Significant
GlaxoSmithKline plc (ADR) (NYSE:GSK) bagged the Food and Drug Administration approval on Wednesday for its latest respiratory medicine, Nucala, to treat severe asthma in combination with other drugs.
GlaxoSmithKline plc (ADR), AbbVie Inc: Attractive High-Yield Dividend Pharma ...
In the Big Pharma space, there are plenty of high-yield stocks out there that are ripe for the picking. Two in particular that investors should consider are AbbVie (NYSE:ABBV) and an international pharmaceutical giant, GlaxoSmithKline (NYSE:GSK).
Is GlaxoSmithKline plc (ADR) On The Path To Recovery?
GlaxoSmithKline Plc ADR (NYSE:GSK) announced its five-year growth plans, intended to reinstate investors' trust in the drug maker.